# US 2015/0147322 A1 · Compositions and methods for targeting type 1 interferon producing cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147322 A1
- Document ID: US20150147322A1
- Status: Published application
- Kind: A1
- Application number: 14/617,882
- Filed: 2015-02-09
- Published: 2015-05-28
- Earliest claimed: 2009-02-18
- Assignees: CSL Limited
- Applicants: CSL Limited
- Inventors: Gino Luigi VAIRO; Andrew NASH; Eugene MARASKOVSKY; Nick WILSON; Samantha BUSFIELD; Con PANOUSIS
- Web page: https://patentgrep.com/patent/US20150147322A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/202: {IL-3}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 51/1021: {against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons}
- A61K 51/1033: {against receptors for cytokines, lymphokines or interferons}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07K 16/244: {Interleukins [IL]}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

## Claims

### Claim at position 1

-30. (canceled)

### Claim 31

A method of treating lupus in a mammal, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and competitively inhibits the binding of monoclonal antibody 7G3 to IL-3Rα and which depletes or at least partly eliminates plasmacytoid dendritic cells (pDCs) and basophils to which it binds to thereby treat lupus in the mammal, wherein the immunoglobulin is not conjugated to a toxic compound that kills a cell to which the immunoglobulin binds, and wherein the immunoglobulin is capable of inducing an enhanced level of effector function.

### Claim 32 (depends on 31)

The method of claim 31, wherein the lupus is systemic lupus erythematosus (SLE)

### Claim 33 (depends on 31)

The method of claim 31, wherein the IL-3Rα chain is expressed by a pDC that produces one or more type I interferons and/or wherein the IL-3Rα chain is expressed by a basophil that produces one or more cytokines

### Claim 34 (depends on 31)

The method of claim 31, wherein the immunoglobulin binds to the same epitope as monoclonal antibody 7G3 or an overlapping epitope.

### Claim 35 (depends on 31)

The method of claim 31, wherein the immunoglobulin neutralizes IL-3 signaling.

### Claim 36 (depends on 31)

The method of claim 31, wherein the immunoglobulin is an antibody or an antigen binding fragment thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the antibody is a chimeric antibody.

### Claim 38 (depends on 37)

The method of claim 37, wherein the chimeric antibody is a chimeric antibody comprising the variable regions of monoclonal antibody 7G3.

### Claim 39 (depends on 36)

The method of claim 36, wherein the antibody is a humanized antibody.

### Claim 40 (depends on 39)

The method of claim 39, wherein the humanized antibody is a humanized antibody comprising complementarity determining regions derived from monoclonal antibody 7G3.

### Claim 41 (depends on 40)

The method of claim 40, wherein the humanized antibody comprises a light chain variable region (VL) comprising a sequence set forth in SEQ ID NO: 3 and a heavy chain variable region (VH) comprising a sequence set forth in SEQ ID NO: 2.

### Claim 42 (depends on 36)

The method of claim 36, wherein the antibody is a human antibody.

### Claim 43 (depends on 31)

The method of claim 31, wherein the effector function is antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and/or complement dependent cytotoxicity (CDC).

### Claim 44 (depends on 31)

The method of claim 31 wherein the level of effector function induced by the immunoglobulin is enhanced relative to that of the immunoglobulin when it comprises a wild-type IgG1 Fc region or chimeric 7G3 or hz7G3 (comprising light chain comprising a sequence set forth in SEQ ID NO: 5 and a heavy chain comprising a sequence set forth in SEQ ID NO: 4).

### Claim 45 (depends on 31)

The method of claim 31, wherein the immunoglobulin comprises a Fc region that is afucosylated.

### Claim 46 (depends on 31)

The method of claim 31, wherein the immunoglobulin comprises an Fc portion comprising one or more amino acid sequence substitutions that enhance the effector function induced by the immunoglobulin.

### Claim 47 (depends on 46)

The method of claim 46, wherein the one or more amino acid sequence substitutions are:
(i) S239D, A330L and I332E according to the EU numbering system of Kabat; or
(ii) S239D and I332E according to the EU numbering system of Kabat.

### Claim 48 (depends on 47)

The method of claim 47, wherein the immunoglobulin is and antibody comprising a light chain comprising a sequence set forth in SEQ ID NO: 5 and a heavy chain comprising a sequence set forth in SEQ ID NO: 7 (hz7G3V2).

### Claim 49 (depends on 31)

The method of claim 31, wherein following administration of the immunoglobulin the number of plasmacytoid dendritic cells (pDCs) and basophils in circulation in the mammal is reduced by at least about 50% compared to the number of the pDCs and/or basophils in circulation in the mammal prior to administering the immunoglobulin.

### Claim 50 (depends on 49)

The method of claim 49, wherein at least about six hours following administration of the immunoglobulin, the number of pDCs and basophils in circulation in the mammal is reduced by at least about 50% compared to the number of the pDCs and/or basophils in circulation in the mammal prior to administering the immunoglobulin.

### Claim 51 (depends on 49)

The method of claim 49, wherein the number of pDCs and basophils in circulation in the mammal is reduced by at least about 50% compared to the number of pDCs and/or basophils in circulation in the mammal prior to administering the immunoglobulin for at least 7 days post administration without further administrations of the immunoglobulin.

### Claim 52 (depends on 31)

The method of claim 31 comprising administering between about 0.001 mg/kg and 50 mg/kg of immunoglobulin to the mammal.

### Claim 53 (depends on 52)

The method of claim 52, wherein the immunoglobulin is administered to the mammal a plurality of times and wherein the period between administrations is at least about 11 days.

### Claim 54

A method of treating lupus in a mammal, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (pDCs) and basophils to which it binds to thereby treat lupus in the mammal, wherein the immunoglobulin is not conjugated to a toxic compound that kills a cell to which the immunoglobulin binds, and wherein the immunoglobulin is capable of inducing an enhanced level of effector function.

### Claim 55 (depends on 54)

The method of claim 54, wherein the immunoglobulin neutralizes IL-3 signaling.

### Claim 56 (depends on 55)

The method of claim 55, wherein the immunoglobulin and competitively inhibits the binding of monoclonal antibody 7G3 to IL-3Rα.
